Moayed Ibrahim1, Kshama Bhyravabhotla2, Basil Khalaf3, Keith Van Meter3, Nakhle S Saba4, Hana Safah4, Francisco Socola4. 1. Section of Hematology and Medical Oncology, Deming Department of Medicine, School of Medicine, Tulane University, 1430 Tulane Ave., Mailbox#8078, New Orleans, LA, 70112-2699, USA. mibrahim1@tulane.edu. 2. Section of Pediatrics-Internal Medicine, Deming Department of Medicine, Tulane University, New Orleans, LA, USA. 3. Section of Undersea and Hyperbaric Medicine, Department of Emergency Medicine, Louisiana State University, New Orleans, LA, USA. 4. Section of Hematology and Medical Oncology, Deming Department of Medicine, School of Medicine, Tulane University, 1430 Tulane Ave., Mailbox#8078, New Orleans, LA, 70112-2699, USA.
Abstract
BACKGROUND: To date, there are only a few case reports of cyclophosphamide (Cy)-induced hemorrhagic cystitis (HC) in adult or pediatric allogeneic stem cell transplant (SCT) patients treated successfully with hyperbaric oxygen (HBO). In all the reported cases, Cy was used as a part of the conditioning regimen, rather than post-transplant for graft-versus-host-disease (GVHD) prophylaxis. More recently, the risk of HC in allogeneic SCT is further increased by the widespread use of post-transplantation cyclophosphamide (PTCy) as a highly effective strategy for GVHD prophylaxis. This is the first case reported of PTCy-induced HC successfully treated with HBO to the best of our knowledge. CASE PRESENTATION: In this article, we present a 58-year-old Caucasian male case of allogeneic SCT complicated by severe HC following PTCy, which was successfully treated with HBO, eliminating the need for cystectomy. CONCLUSION: HBO can be a safe, noninvasive, alternative treatment modality for PTCy-induced HC developing in allogeneic SCT patients.
BACKGROUND: To date, there are only a few case reports of cyclophosphamide (Cy)-induced hemorrhagic cystitis (HC) in adult or pediatric allogeneic stem cell transplant (SCT) patients treated successfully with hyperbaric oxygen (HBO). In all the reported cases, Cy was used as a part of the conditioning regimen, rather than post-transplant for graft-versus-host-disease (GVHD) prophylaxis. More recently, the risk of HC in allogeneic SCT is further increased by the widespread use of post-transplantation cyclophosphamide (PTCy) as a highly effective strategy for GVHD prophylaxis. This is the first case reported of PTCy-induced HC successfully treated with HBO to the best of our knowledge. CASE PRESENTATION: In this article, we present a 58-year-old Caucasian male case of allogeneic SCT complicated by severe HC following PTCy, which was successfully treated with HBO, eliminating the need for cystectomy. CONCLUSION: HBO can be a safe, noninvasive, alternative treatment modality for PTCy-induced HC developing in allogeneic SCT patients.
Authors: Christopher G Kanakry; Hua-Ling Tsai; Javier Bolaños-Meade; B Douglas Smith; Ivana Gojo; Jennifer A Kanakry; Yvette L Kasamon; Douglas E Gladstone; William Matsui; Ivan Borrello; Carol Ann Huff; Lode J Swinnen; Jonathan D Powell; Keith W Pratz; Amy E DeZern; Margaret M Showel; Michael A McDevitt; Robert A Brodsky; Mark J Levis; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik Journal: Blood Date: 2014-10-14 Impact factor: 22.113
Authors: L E Lunde; S Dasaraju; Q Cao; C S Cohn; M Reding; N Bejanyan; B Trottier; J Rogosheske; C Brunstein; E Warlick; J A H Young; D J Weisdorf; C Ustun Journal: Bone Marrow Transplant Date: 2015-07-13 Impact factor: 5.483
Authors: S Cesaro; A Brugiolo; M Faraci; C Uderzo; R Rondelli; C Favre; M Zecca; G Garetto; G Dini; M Pillon; C Messina; L Zanesco; A Pession; F Locatelli Journal: Bone Marrow Transplant Date: 2003-11 Impact factor: 5.483